Harnessing CRISPR-Cas9 Gene-Editing Technology in Cancer Research: Challenges and Opportunities from an MI Analyst's Perspective

This article explores the challenges and opportunities of CRISPR-Cas9 gene-editing technology in cancer research from the perspective of a Management Information analyst. It examines key scientific and technical barriers such as delivery methods, off-target effects, and tumor microenvironment complexity that currently restrict the clinical application of CRISPR in oncology. The article integrates data-driven insights to emphasize how advanced analytics and robust data strategies can aid in overcoming these challenges. Future directions include interdisciplinary collaboration and innovation in delivery systems, predictive modeling, and multi-modal therapeutic integration. This work contributes an analytic viewpoint bridging data science and biomedical research to advance precision oncology.